NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Income Statement
OSL:NYKD - Euronext Oslo - NO0010714785 - Common Stock - Currency: NOK
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.68M | 12.90M | 7.17M | 33.96M | 215.00M | |||
| Operating Expenses | 55.81M | 69.26M | 57.83M | 41.69M | 33.66M | |||
| Research and Development | N/A | 29.36M | 26.77M | 16.30M | 10.63M | |||
| Selling, General, and Administrative Expenses | 31.55M | 28.41M | 18.80M | 17.51M | 16.05M | |||
| Operating Income | -47.13M | -56.36M | -50.66M | -7.72M | 181.34M | |||
| Interest Income/Expense | 2.82M | 14.00M | 2.31M | -369.00K | 2.85M | |||
| Other Income/Expense | 0.00 | 0.00 | -137.00K | 27.00K | -211.00K | |||
| Non Recurring Items | -1.20M | -1.72M | -2.49M | -3.05M | -3.08M | |||
| Income Before Taxes | -45.51M | -44.09M | -50.98M | -11.12M | 180.91M | |||
| Income Tax | -6.69M | -8.93M | -8.24M | -1.70M | 31.13M | |||
| Net Income | -38.82M | -35.15M | -42.74M | -9.41M | 149.77M | |||
| EBITDA | -44.88M | -54.24M | -48.85M | -6.99M | 181.64M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.12 | -0.12 | -0.15 | -0.03 | 0.51 | |||
| Non GAAP EPS | -0.12 | -1.26 | N/A | N/A | N/A | |||
| Statistics | ||||||||
| Profit Margin | -447.30% | -272.47% | -596.30% | -27.72% | 69.66% | |||
| Operating Profit Margin | -543.05% | -436.82% | -706.81% | -22.75% | 84.34% | |||
All data in USD (non-GAAP EPS in NOK )